Literature DB >> 18836721

Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells.

Ze Tian1, Ning An, Bin Zhou, Peigen Xiao, Isaac S Kohane, Erxi Wu.   

Abstract

PURPOSE: The aim of the study is to dissect the cytotoxic mechanisms of 1-(4-hydroxy-3-methoxyphenyl)-7-(3,4-dihydroxyphenyl)-4E-en-3-heptanone (compound 1) in SH-SY5Y cells and therefore to provide new insight into neuroblastoma chemotherapy.
METHODS: Nine diarylheptanoids were isolated from Alpinia officinarum by chromatography and their cytotoxicity was evaluated by an MTS assay. Flow cytometry, BrdU incorporation assay and fluorescence staining were employed to investigate cytostatic and apoptotic effects induced by the compound 1. In addition, Western blot, qPCR and siRNA techniques were used to elucidate the molecular mechanisms of the cytotoxicity.
RESULTS: The study to elucidate the cytotoxic mechanisms of compound 1, the most potent diarylheptanoid showed that cell cycle-related proteins, cyclins, CDKs and CDKIs, as well as two main apoptotic related families, caspase and Bcl 2 were involved in S phase arrest and apoptosis in neuroblastoma cell line SH-SY5Y. Furthermore, following the drug treatment, the protein expression of p53, phospho-p53 (Ser20) as well as the p53 transcriptional activated genes ATF3, puma and Apaf-1 were increased dramatically; MDM2 and Aurora A, the two p53 negative regulators were decreased; the p53 protein stability was enhanced, whereas the p53 mRNA expression level slightly decreased and ATF3 mRNA expression apparently increased. In addition, the knockdown of ATF3 gene by siRNA partially suppressed p53, caspase 3, S phase arrest and apoptosis triggered by compound 1.
CONCLUSION: These results suggest that compound 1 induces S phase arrest and apoptosis via up regulation of ATF3 and stabilization of p53 in SH-SY5Y cell line. Therefore, compound 1 might be a promising lead structure for neuroblastoma therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836721      PMCID: PMC3709019          DOI: 10.1007/s00280-008-0832-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  39 in total

1.  Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.

Authors:  Tom Van Maerken; Frank Speleman; Joëlle Vermeulen; Irina Lambertz; Sarah De Clercq; Els De Smet; Nurten Yigit; Vicky Coppens; Jan Philippé; Anne De Paepe; Jean-Christophe Marine; Jo Vandesompele
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 2.  Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.

Authors:  Kelly C Goldsmith; Michael D Hogarty
Journal:  Cancer Lett       Date:  2005-10-18       Impact factor: 8.679

3.  Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice.

Authors:  Jian-Hua Mao; Di Wu; Jesus Perez-Losada; Tao Jiang; Qian Li; Richard M Neve; Joe W Gray; Wei-Wen Cai; Allan Balmain
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

4.  Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.

Authors:  Rana P Singh; Gagan Deep; Marie-José Blouin; Michael N Pollak; Rajesh Agarwal
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

5.  Diarylheptanoids from the rhizomes of Alpinia officinarum and their anticancer activity.

Authors:  Ning An; Zhong-mei Zou; Ze Tian; Xiu-zhen Luo; Shi-lin Yang; Li-zhen Xu
Journal:  Fitoterapia       Date:  2007-08-09       Impact factor: 2.882

6.  Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.

Authors:  Hiroshi Aoki; Yasunari Takada; Seiji Kondo; Raymond Sawaya; Bharat B Aggarwal; Yasuko Kondo
Journal:  Mol Pharmacol       Date:  2007-03-29       Impact factor: 4.436

7.  Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells.

Authors:  K Kurata; R Yanagisawa; M Ohira; M Kitagawa; A Nakagawara; T Kamijo
Journal:  Oncogene       Date:  2007-08-20       Impact factor: 9.867

8.  Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis.

Authors:  Dan Lu; Curt D Wolfgang; Tsonwin Hai
Journal:  J Biol Chem       Date:  2006-02-09       Impact factor: 5.157

Review 9.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

Review 10.  Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research.

Authors:  William P Steward; Andreas J Gescher
Journal:  Mol Nutr Food Res       Date:  2008-09       Impact factor: 5.914

View more
  10 in total

1.  Echinacoside Protects Against MPP(+)-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation.

Authors:  Qing Zhao; Xiaoyan Yang; Dingfang Cai; Ling Ye; Yuqing Hou; Lijun Zhang; Jiwei Cheng; Yuan Shen; Kaizhe Wang; Yu Bai
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

2.  Cambogin is preferentially cytotoxic to cells expressing PDGFR.

Authors:  Ze Tian; Jie Shen; Fengfei Wang; Peigen Xiao; Junshan Yang; Hetian Lei; Andrius Kazlauskas; Isaac S Kohane; Erxi Wu
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

3.  Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells.

Authors:  Saswati Mahapatra; Charles Y F Young; Manish Kohli; R Jeffrey Karnes; Eric W Klee; Michael W Holmes; Donald J Tindall; Krishna Vanaja Donkena
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-22       Impact factor: 2.629

4.  Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis.

Authors:  Qiaowei Fan; Bingrong Liu
Journal:  Onco Targets Ther       Date:  2017-07-19       Impact factor: 4.147

Review 5.  Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine.

Authors:  Jiang-Jiang Qin; Xin Li; Courtney Hunt; Wei Wang; Hui Wang; Ruiwen Zhang
Journal:  Genes Dis       Date:  2018-07-20

6.  ATF3 Suppresses Growth and Metastasis of Clear Cell Renal Cell Carcinoma by Deactivating EGFR/AKT/GSK3β/β-Catenin Signaling Pathway.

Authors:  Shenglin Gao; Lei Gao; Simin Wang; Xiaokai Shi; Chuang Yue; Shuzhang Wei; Li Zuo; Lifeng Zhang; Xihu Qin
Journal:  Front Cell Dev Biol       Date:  2021-03-19

7.  A practical platform for blood biomarker study by using global gene expression profiling of peripheral whole blood.

Authors:  Ze Tian; Nathan Palmer; Patrick Schmid; Hui Yao; Michal Galdzicki; Bonnie Berger; Erxi Wu; Isaac S Kohane
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

Review 8.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

9.  ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression.

Authors:  Cong Chen; Chao Ge; Zheng Liu; Liangyu Li; Fangyu Zhao; Hua Tian; Taoyang Chen; Hong Li; Ming Yao; Jinjun Li
Journal:  J Exp Clin Cancer Res       Date:  2018-10-30

Review 10.  Diarylheptanoids as nutraceutical: A review.

Authors:  G Ganapathy; R Preethi; J A Moses; C Anandharamakrishnan
Journal:  Biocatal Agric Biotechnol       Date:  2019-03-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.